Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis

British Journal of Clinical Pharmacology

Volumn 47, Issue 6, 1999, Pages 645-651

  Pfister, Marc ^b   Schaedeli, Franziska ^b   Frey, Felix J ^b   Uehlinger, Dominik E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

Candesartan cilexetil; Haemodialysis; Hypertension; NONMEM

Indexed keywords

CANDESARTAN HEXETIL;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; HEADACHE; HEAT; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY POLYCYSTIC DISEASE; LEG CRAMP; MALE; METABOLIC CLEARANCE RATE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VERTIGO;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; RENAL DIALYSIS; TETRAZOLES;

EID: 0032996426     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00939.x     Document Type: Article

References (28)

1. 1 Kubo K, Kohara Y, Imamiya E, et al. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids. J Med Chem 1993; 36: 2182-2195.
2. 2 Kubo K, Kohara Y, et al. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. J Med Chem 1993; 36: 2343-2349.
3. 3 Morimoto S, Ogihara T. TCV-116: a new angiotensin II type-1 antagonist Cardiovase Drug Rev 1994; 12: 153-164.
4. 4 Shibouta Y, Inada Y, Ojima M, et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy 1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974) and its prodrug (±)-1 (cyclohexyloxycarbonyloxy)-ethyl-2-ethoxy 1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266: 114-120.
5. 5 Kondo T, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. Drug Res 1996; 46: 594-600.
6. 14C-candesartan cilexetil in healthy volunteers. J Human Hypertension 1997; 11 (Suppl 2): S27-S28.
7. 7 Ogihara T, Nagano M, Mikami H, et al. Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 1994; 16: 74-86.
8. 8 Riddell J. Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil. J Human Hypertension 1997; 11 (Suppl 2): S29 -S30.
9. 9 Ogihara T, Higashimori K, Masuo K, Mikami H. Pilot study of a new angiotensin II receptor antagonist, TCV-116: effects of a single oral dose on blood pressure in patients with essential hypertension. Clin Ther 1993; 15: 684-691.
10. 10 Hübner R, Högemann A, Sunzel M, Riddell J. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Human Hypertension 1997; 11 (Suppl 2): S19-S25.
11. 11 Sever P. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J Human Hypertension 1997; 11 (Suppl 2): S91-S95.
12. 12 Delacretaz E, Nussberger J, Biollaz J, Waeber B, Brunner H. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25: 14-21.
13. 13 Uchlinger D, Schaedeli F, Kinzig M, Soergel F, Frey F. Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular haemodialysis. J Antimicrob Chemother 1996; 40: 1903-1909.
14. 14 Gibaldi M, Perrier D. Clearance concepts. In Pharmacokinetics. Second Edition. New York: Marcel Dekker Inc, 1982; 319-353.
15. 15 Gibson T, Matusik K, Nelson L, Briggs M. Artificial kidneys and clearance calculations. Clin Pharmacol Ther 1977; 20: 720-726.
16. 16 Beal S. Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metab Rev 1984; 15: 173-193.
17. 17 Beal S, Sheiner L. The NONMEM system. Am Stat 1980; 34: 118-119.
18. 18 Boeckmann A, Sheiner L, Beal S. In NONMEM users guide. Part V, 1992. NONMEM Project Group, University of California, San Francisco.
19. 19 Sotaniemi E, Arranto A, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61: 331-339.
20. 20 Sotaniemi E, Luoma P, Jaervensivu P, Sotaniemi K. Impairment of drug metabolism in polycystic non-parasitic: liver disease. Br J Clin Pharmacol 1979; 8: 331-335.
21. 21 De Zeeuw D, Remuzzi G, Kirch W. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Human Hypertension 1997; 11 (Suppl 2): S37-S42.
22. 22 Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996; 31: 47-64.
23. 23 Criscione L, de Gasparo M, Buchlmayer P, Whitebread S, Ramjoué H, Wood J. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 1993; 110: 761-771.
24. 24 Johnston C. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346:1403-1407.
25. 25 Lo M, Goldberg M, McCrea J. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641-649.
26. 26 Vachbarajani N, Chang S, Shyu W. Absolute bioavailability of irbesartan, an angiotensin II receptor antagonist in man. Pharm Res 1995; 12: S418.
27. 27 Von Lutterotti N, Catanzaro D, Sealey J, Laragh J. Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence. Circulation 1994; 89: 458-470.
28. 28 Nussberger J, Flueckiger J, Hui K, Evéquoz D, Waeber B, Brunner H. Angiotensin I and II disappear completely from circulating blood within 48 hours after binephrectomy: improved measurement of angiotensins in rat plasma. J Hypertension 1991; 6 (Suppl): S230-S231.